In the course of our screening for new antitumor antibiotics, pyrindamycins A(l) and B(2) were isolated in the culture broth of Streptomyces sp. SF2582. In the previous papers1'2), we reported the fermentation, isolation, physico-chemical properties, structure elucidation including X-ray analysis of pyrindamycin A, antimicrobial activity and antitumor activity against P388 leukemia of pyrindamycins.
In this paper, wedescribe the m vitro cytotoxic activities, effects on macromolecular syntheses and in vivo antitumor activities of pyrindamycins against various murine tumors.
Materials and Methods

Agents
Pyrindamycins A and B were prepared in our laboratories. Doxorubicin was purchased from Kyowa Hakko Kogyo Co., Ltd., Tokyo, RPMI-1640 medium from Nissui Pharmaceutical Co., Ltd., Tokyo, 3-(4,5-dimethylthiazol-2-yl) - Pyrindamycins A and B were dissolved in dimethyl sulfoxide and diluted with distilled water. MTT was dissolved in phosphate buffered saline (PBS). 
Cell Culture
All cells were cultivated in RPMI-1640 medium supplemented with 10% fetal calf serum and 10|M of2-HEDS at 37°C under 5% CO2 in air. Cell lines and inoculum size are shown in Table 1 .
Animals
Specific pathogen free (SPF) BDFimale mice, 5 weeks old, were supplied from Shizuoka Agricultural Cooperative Association for Experimental Animals, Hamamatsu. Mice were fed with commercial diet (NMF, Oriental Yeast Co., Tokyo) and water ad libitum.
Cytotoxic Activity
Cells were cultivated with 96-well flat-bottomed microplate (Falcon, No. 3002). In the case of suspension culture, drugs were added into the culture mediumimmediately after cell inoculation and cells were cultivated for 72 hours. The viable cell fraction was measured by the modified MTTassay3>4). The modified MTTassay was carried out as follows: After the addition of 10 /il ofMTT solution (5 mg/ml), the microplate was incubated at 37°C for 6 hours. Then a 100-^tl of0.01n HC1-10% SDSmixture was added to each well and further incubated at 37°C for 16 hours for dissolution of MTT-formazan and cell debris. Absorbance of MTTreaction mixture in well was measured at 577nmwith the reference absorbance at 630nm using a ELISA analyser (ETY-96, Oriental Instruments Ltd.). In the case of adherent growth, drugs were added into the culture mediumafter 24 hours. In Vivo Antitumor Activity All in vivo experiments were carried out under SPF conditions. For implantation, cells of P388, P388/ADR, M5076or EL-4 was suspended in Hanks' solution and implanted intraperitoneally to mice at 1 x 106 cells/mouse and 1 x 105 cells/mouse for L1210. B16 cells were implanted intraperitoneally to each mouse with 0.5ml of 1 : 10 tumor brei. Drugs were administered intraperitoneally once a day on days 1, 3 and 5. Each experiment was terminated on the 60th day after inoculation. Antitumor activity was assessed as the percent increase in life span (ILS %) from mean survival time of the drug-treated group and of the control group.
Results
Cytotoxic Activity As shown in Table 2 (open) and P388/ADR (closed) cells. Table 2 . Tumorswere transplantated intraperitoneally and each sample was administered intraperitoneally once a day starting the day after tumor transplantation for three times on days 1, 3 and 5. ILS was calculated by the following Abbreviations: See footnote in Table 2 .
1. The ratios of intracellular accumulation in P388/ADRcompared ,to P388 for pyrindamycins A, B and doxorubicin were 106, 76 and 39%, respectively.
Effect on Macromolecular Synthesis
Effects of pyrindamycins A and B on DNA, RNAand protein synthesis are shown in Table 3 . IC50 values for DNA, RNAand protein synthesis ofpyrindamycin A were 25.6, 194 and 2,030 ng/ml, and those of pyrindamycin B were 4.08, 146 and 2,300ng/ml, respectively. These results showed that both pyrindamycins A and B were specific inhibitors of DNAsynthesis. In Vivo Antitumor Activity In vivo antitumor activity of pyrindamycins A and B are shown in Pyrindamycins A and B also showed therapeutic efficacies to multidrug-resistant cell line, P388/ADR. Furthermore, pyrindamycins A and B were accumulated in P388 and P388/ADR at similar degree. The results suggested that those agents did not undergo rapid efflux from resistant cell lines7)8).
Pyrindamycins A and B inhibited DNAsynthesis more than RNAor protein synthesis and the antibiotics were specific inhibitors of DNAsynthesis. Although pyrindamycin B inhibited DNAsynthesis in CCRF-CEM cells more strongly than pyrindamycin A, the cytotoxic activity of pyrindamycin B against CCRF-CEM was weaker than that of pyrindamycin A. The results suggested that. pyrindamycin A possessed another cytotoxic mechanism.
Both pyrindamycins A and B showed antitumor activities against murine leukemia. Since pyrindamycins A and B exhibited antitumor activity against multidrug-resistant tumor, they might be a candidate as useful chemotherapeutic agents for severe multidrug-resistant tumors9).
